Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Fortress Biotech (FBIO) and Partex NV have announced a strategic collaboration to leverage artificial intelligence for biopharmaceutical asset identification and evaluation. The partnership combines Fortress' expertise in identifying and developing promising assets with Partex's proprietary AI-based drug discovery platform.
Partex's technology will provide comprehensive analyses including target identification, indication expansion, and molecular profiling to accelerate bringing therapeutics to market. The collaboration aims to support Fortress' business model of acquiring and advancing assets to enhance shareholder value through product revenue, equity holdings, and dividend and royalty revenue.
Fortress currently has a late-stage pipeline, two recently approved medicines, and another candidate with a PDUFA date in Q3 2025. The company expects this AI collaboration to enable more efficient and cost-effective scaling of their asset evaluation process.
Fortress Biotech (FBIO) e Partex NV hanno annunciato una collaborazione strategica per sfruttare l'intelligenza artificiale nell'identificazione e valutazione di beni biofarmaceutici. La partnership combina l'esperienza di Fortress nell'identificazione e nello sviluppo di beni promettenti con la piattaforma di scoperta di farmaci basata su IA di Partex.
La tecnologia di Partex fornirà analisi complete, inclusa l'identificazione dei target, l'espansione delle indicazioni e il profilo molecolare, per accelerare la commercializzazione dei terapeutici. La collaborazione mira a sostenere il modello di business di Fortress, che prevede l'acquisizione e il progresso di beni per aumentare il valore per gli azionisti attraverso entrate da prodotto, partecipazioni azionarie e entrate da dividendi e royalties.
Fortress ha attualmente un pipeline in fase avanzata, due farmaci recentemente approvati e un altro candidato con una data PDUFA nel terzo trimestre del 2025. L'azienda si aspetta che questa collaborazione basata su IA consenta una scalabilità più efficiente ed economica del loro processo di valutazione degli asset.
Fortress Biotech (FBIO) y Partex NV han anunciado una colaboración estratégica para aprovechar la inteligencia artificial en la identificación y evaluación de activos biofarmacéuticos. La asociación combina la experiencia de Fortress en la identificación y desarrollo de activos prometedores con la plataforma de descubrimiento de fármacos basada en IA de Partex.
La tecnología de Partex proporcionará análisis exhaustivos, incluyendo la identificación de objetivos, la expansión de indicaciones y el perfil molecular, para acelerar la comercialización de terapéuticos. La colaboración tiene como objetivo apoyar el modelo de negocio de Fortress de adquirir y avanzar activos para aumentar el valor para los accionistas a través de ingresos por productos, participaciones en acciones y ingresos por dividendos y regalías.
Fortress cuenta actualmente con un pipeline en etapa avanzada, dos medicamentos recientemente aprobados y otro candidato con una fecha PDUFA en el tercer trimestre de 2025. La empresa espera que esta colaboración basada en IA permita una escalabilidad más eficiente y rentable de su proceso de evaluación de activos.
포트리스 바이오텍 (FBIO)와 파르텍 NV는 생물 제약 자산 식별 및 평가를 위해 인공지능을 활용하는 전략적 협력을 발표했습니다. 이 파트너십은 유망 자산을 식별하고 개발하는 포트리스의 전문성과 파르텍의 독자적인 AI 기반 약물 발견 플랫폼을 결합합니다.
파르텍의 기술은 목표 식별, 적응증 확대 및 분자 프로파일링을 포함한 포괄적인 분석을 제공하여 치료제를 시장에 더 빨리 출시할 수 있도록 합니다. 이 협력은 포트리스의 비즈니스 모델을 지원하여 제품 수익, 지분 보유 및 배당금 및 로열티 수익을 통해 주주 가치를 향상시키는 것을 목표로 합니다.
현재 포트리스는 후기 단계 파이프라인을 보유하고 있으며, 최근 승인된 약물 두 가지와 2025년 3분기에 PDUFA 날짜가 있는 또 다른 후보를 보유하고 있습니다. 회사는 이 AI 협력이 자산 평가 프로세스를 보다 효율적이고 비용 효과적으로 확장할 수 있도록 할 것으로 기대하고 있습니다.
Fortress Biotech (FBIO) et Partex NV ont annoncé une collaboration stratégique pour tirer parti de l'intelligence artificielle dans l'identification et l'évaluation d'actifs biopharmaceutiques. Ce partenariat combine l'expertise de Fortress dans l'identification et le développement d'actifs prometteurs avec la plateforme de découverte de médicaments basée sur l'IA de Partex.
La technologie de Partex fournira des analyses complètes, y compris l'identification des cibles, l'expansion des indications et le profilage moléculaire, afin d'accélérer la mise sur le marché des thérapeutiques. La collaboration vise à soutenir le modèle économique de Fortress qui consiste à acquérir et à faire progresser des actifs pour augmenter la valeur pour les actionnaires grâce aux revenus des produits, aux participations et aux revenus de dividendes et de redevances.
Fortress dispose actuellement d'un pipeline en phase avancée, de deux médicaments récemment approuvés et d'un autre candidat avec une date PDUFA au troisième trimestre 2025. L'entreprise s'attend à ce que cette collaboration basée sur l'IA permette une évaluation des actifs plus efficace et rentable.
Fortress Biotech (FBIO) und Partex NV haben eine strategische Zusammenarbeit angekündigt, um künstliche Intelligenz zur Identifizierung und Bewertung biopharmazeutischer Vermögenswerte zu nutzen. Die Partnerschaft kombiniert Fortresses Expertise in der Identifizierung und Entwicklung vielversprechender Vermögenswerte mit der proprietären, auf KI basierenden Arzneimittelentdeckungsplattform von Partex.
Die Technologie von Partex wird umfassende Analysen bereitstellen, darunter Zielidentifikation, Indikationsausweitung und molekulare Profilierung, um die Markteinführung von Therapeutika zu beschleunigen. Die Zusammenarbeit zielt darauf ab, das Geschäftsmodell von Fortress zu unterstützen, das den Erwerb und die Weiterentwicklung von Vermögenswerten umfasst, um den Shareholder-Value durch Produktumsätze, Beteiligungen und Einnahmen aus Dividenden und Lizenzgebühren zu steigern.
Fortress hat derzeit eine Pipeline in der späten Phase, zwei kürzlich genehmigte Arzneimittel und einen weiteren Kandidaten mit einem PDUFA-Datum im dritten Quartal 2025. Das Unternehmen erwartet, dass diese KI-Zusammenarbeit eine effizientere und kostengünstigere Skalierung ihres Vermögensbewertungsprozesses ermöglicht.
- Two medicines already approved and third pending FDA approval in Q3 2025
- AI integration expected to reduce costs and improve efficiency in asset evaluation
- Robust late-stage pipeline in place
- Strategic expansion of evaluation capabilities through AI technology
- None.
Insights
Fortress Biotech's partnership with Partex represents a strategic move to enhance their established business development model using AI technology. While this collaboration won't drive immediate revenue, it's designed to optimize Fortress's core strategy of identifying, acquiring, and advancing promising biopharmaceutical assets.
The deal highlights Fortress's multi-pronged approach to growth: they have a late-stage pipeline, two recently approved medicines, and another candidate with a PDUFA date in Q3 2025. This AI integration aims to make their asset identification process more efficient and cost-effective, potentially increasing the volume and quality of compounds they evaluate.
For context, AI adoption in pharma development is accelerating, with successful implementations reducing discovery timelines by 1-2 years and cutting costs by 20-30% in ideal scenarios. However, the collaboration announcement lacks specific operational metrics, financial terms, or exclusivity details that would help quantify potential impact.
This partnership should be viewed as an enhancement to Fortress's existing systems rather than a transformative event. They already utilize a network of Key Opinion Leaders for asset evaluation, suggesting the AI platform will supplement rather than replace current methods. The long-term value proposition appears sound, but investors should expect gradual implementation benefits rather than immediate financial impact.
This collaboration between Partex and Fortress Biotech highlights the strategic integration of AI into traditional pharmaceutical business development processes. Partex's platform offers three critical capabilities that could significantly enhance Fortress's pipeline development: target identification, indication expansion, and molecular profiling.
The value of this partnership lies in acceleration and efficiency gains. Traditional drug asset evaluation requires extensive manual review of scientific literature, clinical data, and market research - often taking months per asset. AI systems can compress this timeline to days or weeks while processing exponentially more data points.
However, the implementation realities warrant measured expectations. First-generation pharma AI partnerships often underdeliver initially as systems require training on company-specific data and workflows. The announcement lacks details on implementation timelines, specific AI capabilities, or how Fortress will integrate these recommendations with their existing KOL network.
From a competitive standpoint, this move helps Fortress keep pace with larger pharma players who have made significant AI investments. The partnership potentially offers Fortress the advantages of AI-enhanced drug discovery without the $50-100 million investment typically required to build such capabilities in-house.
While representing sound strategic thinking, this collaboration is unlikely to impact near-term financial performance or fundamentally alter Fortress's business trajectory. Its value should be assessed as a gradual enhancement to operational capabilities rather than a catalyst for immediate growth.
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress.
Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers diverse recommendations on alternative targets or indications and helps search and evaluate compounds across therapeutic areas.
“This strategic collaboration leverages the synergistic strengths of both organizations,” said Dr. Frank Grams, Chief Commercial Officer, Partex. “Fortress’ expertise in identifying promising biopharmaceutical assets and advancing them through clinical development to their full potential, coupled with Partex's advanced AI-driven platform, will enable a highly efficient and data-rich approach to identifying, evaluating, and potentially repositioning promising bio-pharmaceutical assets.”
Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative therapeutics faster to market.
Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, also added, “In addition to the advancement of our robust late-stage pipeline of compelling product candidates at Fortress along with our partner companies and subsidiaries, plus the launch of two recently approved medicines and a third with a Prescription Drug User Fee Act (PDUFA) action date in the third quarter of this year, we are also focused on business development opportunities and expanding our portfolio. This collaboration with Partex will allow us to expeditiously identify and evaluate assets using their AI platform in conjunction with our already-established large network of Key Opinion Leaders in various therapeutic areas. The Fortress business model is focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. We believe utilizing AI technology will allow us to scale more efficiently and cost effectively going forward.”
The collaboration is expected to expedite and support the process of search and evaluation to in-license differentiated assets, with both companies committed to utilize AI to its fullest potential.
About Partex
Partex is a pioneering AI-driven biopharmaceutical company dedicated to revolutionizing drug discovery and development. By harnessing cutting-edge AI technologies, Partex aims to accelerate the identification, development, and commercialization of breakthrough therapies.The company’s proprietary platform uses advanced techniques to identify new drug candidates, predict therapeutic applications, and accelerate the in & out-licensing process, helping to bring novel therapies to market faster. Partex aims to be the largest AI-powered Drug Assets Manager solving inefficiencies in the Life sciences Industry.
For more information, visit: https://www.partex.io/ and https://www.linkedin.com/company/partexnv/
Partex Contact:
Nidhi Duhan
Business Operations Manager
Partex NV
Info@partex.io
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com.
Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of products under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.
Fortress Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Fortress Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
What is the purpose of FBIO's collaboration with Partex announced in March 2025?
How many approved medicines does FBIO have in its portfolio as of March 2025?
What specific capabilities will Partex's AI platform provide to FBIO?
How does FBIO plan to generate value for shareholders through this AI collaboration?
